Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

By Sriparna Roy (Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

Topline results were announced from two phase 3 trials evaluating itepekimab, an anti-interleukin-33 monoclonal antibody, in former smokers with inadequately controlled chronic obstructive pulmonary ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

New tools, treatment options, and precision medicine developments are leading to better quality of life and survival for ...

Explore the future of the COPD market with our comprehensive report covering 68 geographic markets. Forecast drug sales growth from $17.4B in 2023 to $42.2B by 2033, driven by the US market. Gain ...